Allergies
Targeting p110delta Protein to Treat Asthma and Allergies
Filed in archive Allergy Medications , Allergy: Research and Development , Asthma by ruth on February 16, 2008
Targeting p110delta Protein to Treat Asthma and Allergies
Scientists have identified a new target for treating asthma and allergies: a protein called p110delta. Unlike currently available asthma and allergy medications in the market which only address the symptoms, medicines targeting this protein can block allergic reactions even before symptoms occur.
More recently, Genentech and Novartis AG have introduced a new medicine for severe asthma called Xolair that blocks a immune system substance called immunoglobulin E, but this still needs to be given as an injection.

A new drug targeting p110delta, by contrast, could be made as a capsule or be adapted for inhalation or topical use, in the case of eczema.

If all goes well, the result could be a therapy that is available for widespread use against allergies and, potentially, other inflammatory conditions such as rheumatoid arthritis.

Source: Reuters



Permalink: Targeting p110delta Protein to Treat Asthma and Allergies
Tags: asthma  allergies  drug+development  allergy+treatment  allergy+medicine  allergy+medication  allergy  asth 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/113789
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Targeting p110delta Protein to Treat Asthma and Allergies:

  • Currently 10.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 10.00 out of 4 vote(s) cast.
 
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!